

Ref: EPL/CS/SE/0019/2024

Date: October 28, 2024

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,


Subject: Press Release

Please find enclosed herewith a Press Release titled "Emcure Pharma Strengthens its Derma Portfolio with the launch of Emcutix Biopharmaceuticals Limited".

You are requested to take the same on your records.

Thanking you,

For Emcure Pharmaceuticals Limited



Chetan Sharma

Company Secretary & Compliance Officer

Membership Number: F8352

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India

Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060

E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** U24231PN1981PLC024251

Press Release**Emcure Pharma Strengthens its Derma Portfolio with the launch of
Emcutix Biopharmaceuticals Limited**

Mumbai, October 28, 2024 – Emcure Pharmaceuticals Limited (“Emcure”), a leading Indian Pharma company, is set to cater to a growing dermatology segment in India with formation of a wholly-owned subsidiary, Emtcutix Biopharmaceuticals Limited. As a part of this strategic initiative, Emcure's existing dermatology business will also operate under Emtcutix. With a renewed focus and a dedicated team, the newly setup entity plans to significantly expand Emcure’s offerings. The focus will be on building a differentiated product portfolio including first-time launches designed to fulfil the unmet needs of the Indian dermatology market.

The market is seeing strong growth primarily driven by a growing population. As per IQVIA, the Indian dermatology market stands at \$1.84 Bn (MAT sales July 2024). The Indian consumers are becoming increasingly conscious of skin health, driving the need for both therapeutic and aesthetic skin care products.

Speaking on the future growth of dermatology, CEO and Managing Director of Emcure Pharmaceuticals Limited, Satish Mehta stated, “The dermatology market in India, is experiencing a significant surge in both value and unit consumption. Emcure is well-positioned to cater to the unmet needs of the Indian market. With a dedicated entity, Emcure aims to concentrate on developing and introducing both prescription and consumer dermatology solutions.”

Emcutix will be spearheaded by G. Sathya Narayanan, who brings with him over three decades of extensive experience in the dermatology sector, with his last stint as the Managing Director of Galderma for South Asia (including India). His notable career includes building some of the most iconic brands in prescription, consumer, and aesthetic dermatology.

Commenting on his new role with Emtcutix, Sathya Narayanan said, “Emcutix represents a unique opportunity with derma care solutions for healthcare professionals, patients and consumers by developing a differentiated dermatology portfolio. Building on Emcure’s legacy of innovation, I look forward to building a portfolio of products that will make a meaningful difference in skin health in India.”

About Emcure Pharmaceuticals Limited: Emcure is a leading Indian pharmaceuticals company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Known for its commitment to innovation, quality, and patient-centricity, Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Established in 1981, Emcure is ranked as the 12th largest pharma company in India in terms of Domestic Sales for MAT June 2024*. Emcure is present in 70+ countries globally including Europe and Canada.

**As reported by market research firm Pharmarack*